149 related articles for article (PubMed ID: 36516528)
1. A prognostic nomogram incorporating tumor size and lymph node size for patients with nasopharyngeal carcinoma.
Yi Q; Cai J; Lin Y; Hu Z; Lin J; Huang Z; Liu W; Zheng R; Yuan Y; Chen C
Am J Otolaryngol; 2023; 44(2):103717. PubMed ID: 36516528
[TBL] [Abstract][Full Text] [Related]
2. Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases.
Ma J; Zhao R; Wu YL; Liu Y; Jin GQ; Su DK
Cancer Imaging; 2023 Dec; 23(1):123. PubMed ID: 38102725
[TBL] [Abstract][Full Text] [Related]
3. The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy.
Wan Y; Tian L; Zhang G; Xin H; Li H; Dong A; Liang Y; Jing B; Zhou J; Cui C; Chen M; Sun Y; Xie C; Liu L; Shao Y
Radiother Oncol; 2019 Feb; 131():35-44. PubMed ID: 30773185
[TBL] [Abstract][Full Text] [Related]
4. Significance of radiologic extranodal extension in locoregionally advanced nasopharyngeal carcinoma with lymph node metastasis: a comprehensive nomogram.
Ding J; Chen J; Lin Y; Hong J; Huang C; Fei Z; Chen C
Braz J Otorhinolaryngol; 2024; 90(2):101363. PubMed ID: 38101121
[TBL] [Abstract][Full Text] [Related]
5. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.
Sun XS; Xiao ZW; Liu SL; Sun R; Luo DH; Chen QY; Mai HQ
Eur Radiol; 2023 May; 33(5):3682-3692. PubMed ID: 36735041
[TBL] [Abstract][Full Text] [Related]
6. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.
Peng WS; Xing X; Li YJ; Ding JH; Mo M; Xu TT; Zhou X; Hu CS
Oral Oncol; 2023 Sep; 144():106438. PubMed ID: 37437499
[TBL] [Abstract][Full Text] [Related]
7. Establishment and validation of a novel nomogram to predict overall survival in nasopharyngeal carcinoma with lymph node metastasis.
Li W; Lu H; Wang H; Hu L; Sun X; Yu H; Wang D
Head Neck; 2021 Aug; 43(8):2353-2363. PubMed ID: 33780078
[TBL] [Abstract][Full Text] [Related]
8. Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases.
Lin C; Sun XS; Liu SL; Li XY; Lu N; Li XL; Tang LQ; Guo L
Cancer Res Treat; 2020 Jul; 52(3):855-866. PubMed ID: 32164051
[TBL] [Abstract][Full Text] [Related]
9. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
10. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
[TBL] [Abstract][Full Text] [Related]
11. Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
Yang H; Zhang R; Zhang R; Zhang B; Xie Y; Qin G; Mo Y; Ruan X; Jiang W
Strahlenther Onkol; 2022 Sep; 198(9):828-837. PubMed ID: 35384452
[TBL] [Abstract][Full Text] [Related]
12. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
[TBL] [Abstract][Full Text] [Related]
13. MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it.
Li WZ; Liu GY; Lin LF; Lv SH; Qiang MY; Lv X; Wu YS; Liang H; Ke LR; Wang DL; Yu YH; Qiu WZ; Liu KY; Guo X; Li JP; Zou YJ; Xiang YQ; Xia WX
Radiother Oncol; 2020 Apr; 145():101-108. PubMed ID: 31931288
[TBL] [Abstract][Full Text] [Related]
14. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers.
Lai C; Zhang C; Lv H; Huang H; Ke X; Zhou C; Chen H; Chen S; Zhou L
Cancer Med; 2021 Jun; 10(11):3511-3523. PubMed ID: 33973727
[TBL] [Abstract][Full Text] [Related]
15. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
16. Prognosis viewing for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: application of nomogram and decision curve analysis.
Fei Z; Qiu X; Li M; Chen C; Li Y; Huang Y
Jpn J Clin Oncol; 2020 Feb; 50(2):159-168. PubMed ID: 31711182
[TBL] [Abstract][Full Text] [Related]
17. Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.
Li Z; Li C; Yang D; Zhou Z; Kang M
Biomed Res Int; 2023; 2023():7126881. PubMed ID: 36704722
[TBL] [Abstract][Full Text] [Related]
18. A dynamic nomogram combining tumor stage and magnetic resonance imaging features to predict the response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.
Jiang Y; Liang Z; Chen K; Li Y; Yang J; Qu S; Li L; Zhu X
Eur Radiol; 2023 Mar; 33(3):2171-2184. PubMed ID: 36355201
[TBL] [Abstract][Full Text] [Related]
19. A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.
Sun MX; Zhao MJ; Zhao LH; Jiang HR; Duan YX; Li G
Radiat Oncol; 2023 Apr; 18(1):67. PubMed ID: 37041545
[TBL] [Abstract][Full Text] [Related]
20. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
